Shares of Aprea Therapeutics Inc. (NASDAQ:APRE), a company focused on developing therapies that reactivate the mutant tumor suppressor protein p53, fell 78.1% to $5.50 on Dec. 28, just north of its cash balance, after a pivotal trial of its lead candidate missed its endpoint, leaving the asset's future hazy and likely scuttling plans the company had for a first quarter 2021 NDA filing.
Clinical updates, including trial initiations, enrollment status and data readouts and publications: Aim Immunotech, Algernon, Aprea, Gannex, Inovio, Lysogene, Novavax, Taiwan Liposome.
Clinical updates, including trial initiations, enrollment status and data readouts and publications: BMS, Dynavax, Evaxion, Macrogenics, Modag, Oramed, Palvella, Rakuten, Revive, Serum Institute of India, Spectrum, Supernus.
Amsterdam-based Uniqure NV’s regulatory hitch with its highly regarded hemophilia B program had analysts questioning during a conference call what the development might mean for the company’s deal with CSL Ltd.
HONG KONG – Shanghai Junshi Biosciences Co. Ltd.’s toripalimab has reached its prespecified primary endpoint of progression-free survival at the interim analysis of a phase III study in non-small-cell lung cancer (NSCLC), as efforts to expand approval of the anti-PD-1 antibody into other cancer types are underway.
An evolving COVID-19 treatment paradigm may have foiled Mesoblast Ltd.’s phase III with remestemcel-L in ventilator-dependent patients with moderate to severe acute respiratory distress syndrome (ARDS), CEO Silviu Itescu said, but hope remains in pediatric steroid-refractory acute graft-vs.-host disease (GVHD).
Edwards Lifesciences Corp. launched a pivotal trial of its mitral valve repair system in the U.S., with the first patient undergoing treatment for severe degenerative mitral valve regurgitation at the University of Maryland Medical Center in Baltimore. Open-heart surgery is the current standard approach to mitral valve repair, but the Harpoon Beating Heart mitral valve repair system allows surgeons to use a minimally invasive approach, according to Edwards Lifesciences.
The challenging mucositis space chalked up another failure in dusquetide, the innate defense regulator from Soligenix Inc., which fell short in a pivotal, phase III study that enrolled 268 patients to test the small-molecule peptide. “We sort of thought so,” Dawson James analyst Jason Kolbert in a Dec. 22 report, with a neutral rating and no price target.
Amsterdam-based Uniqure NV’s regulatory hitch with its highly regarded hemophilia B program had analysts questioning during a conference call what the development might mean for the company’s deal with CSL Ltd.
RSS
